Jingrong Jean Cui

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

Cancer Biology, Tumor Biology, C-met Kinase +20

Safety and preliminary clinical activity of repotrectinib in patients with advanced <i>ROS1</i> fusion-positive non-small cell lung cancer (TRIDENT-1 study).

Byoung Chul Cho, Alexander Drilon, Robert C. Doebele et al. · Journal of Clinical Oncology · 2019 · 71 citations

Trident-1 Study, Pathology, Tumor Biology +17

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Molecular Cancer Therapeutics · 2012 · 70 citations · Full text

Tumor Biology, C-met Pathway, Oncology +14

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications

Jingrong Jean Cui · Expert Opinion on Therapeutic Patents · 2007 · 62 citations

Potential Therapeutic Applications, Tumor Biology, Fibroblast Growth Factor +20